跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CO-DIOVAN 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack - TGA Drug Approval Details
Approvals
/
TGA
/
CO-DIOVAN 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack
Approved
STANDARD
CO-DIOVAN 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack
Novartis Pharmaceuticals Australia Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
May 30, 2025
Approval ID
6e4a1c6bf96eb620
Company
Novartis Pharmaceuticals Australia Pty Ltd
Type
Standard
Approval Details
Approval Id
6e4a1c6bf96eb620
Product Name
CO-DIOVAN 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack
Artg Id
96742
Artg Name
CO-DIOVAN 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Company Detail Path
/organization/novartis-pharmaceuticals-australia-pty-ltd
Artg Date
2005-05-31
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Consumer Medicine Info
http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2009-CMI-00089-3
Product Information
http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2009-PI-00044-3
Active Ingredients
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
May 30, 2025
Approval ID
6e4a1c6bf96eb620
Type
Standard
Back to TGA Approvals